Skip to main content
< Back
About
About the conference
Latest updates
Organisers & Partners
App
Press room
Programme 19
Full programme
Tracks
Speakers 19
Keynote speakers
All speakers
Side events 19
Venue 19
About the venue
Location
Rooms
Subscribe
Infectious diseases
Sessions
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Infectious diseases — E-health
Infectious diseases — Harm reduction
Infectious diseases — Monitoring
Infectious diseases — New trends
Opiates
Infectious diseases — Opiates
Infectious diseases — Programme evaluation
Infectious diseases — Vulnerable groups
Wednesday, 23 October
13:20
Treatment — challenges, determinants and responses
13:20
to
14:50
Networking zone 3 (N3)
Dominique Lopez
The future of hepatitis C among people who inject drugs
13:20
to
14:50
Main stage
Dagmar Hedrich
Erika Duffell
Improving delivery of healthcare programmes
13:20
to
14:50
Central square 3 (C3)
Graça Vilar
Risk behaviours in context
13:20
to
14:50
Networking zone 2 (N2)
Anja Busse
15:00
Practical tools developed under the EMCDDA ‘Harm reduction initiative’
Enhancing the role of drug treatment services for HCV elimination among people who inject drugs
15:00
to
16:30
Central square 1 (C1)
Dagmar Hedrich
Matthew Hickman
Epidemiology of hepatitis C among people who use drugs — Data to inform future planning
15:00
to
16:30
Insights zone 3 (I3)
Vana Sypsa
Jack Stone
16:50
Closing the gaps: HIV and Hepatitis continuum of care with a focus on people who inject drugs
16:50
to
18:20
Central square 1 (C1)
Viktor Mravčík
Thursday, 24 October
13:20
Injecting, risk and reducing harm
13:20
to
14:50
Networking zone 3 (N3)
Thomas Néfau
Evidence to guide future practice and policy
Enhancing hepatitis C treatment outcomes among people who use drugs
13:20
to
14:50
Insights zone 1 (I1)
Catharina Matheï
Adrian Dunlop
16:50
Striving towards the future elimination of Hep C among people who use drugs
16:50
to
18:20
Futures zone 1 (F1)
Eberhard Schatz
Perrine Roux
18:30
Developing new prevention strategies to improve the situation of clients and employees of harm reduction services
18:30
to
19:30
Networking zone 2 (N2)
Gabi Becker
Challenges for harm reduction II
18:30
to
19:30
Insights zone 3 (I3)
Alessandro Pirona
Friday, 25 October
10:45
Epidemiology of infectious diseases
10:45
to
12:15
Insights zone 4 (I4)
Thomas Seyler
Opioid-related deaths: learning from epidemiological studies
10:45
to
12:15
Insights zone 3 (I3)
Sarah Welch
Presentations
Plenary session
Poster session
Big debate
Structured session
Workshop
Oral presentation session
Short communication session
Poster guided tour
Wednesday, 23 October
13:20
Oral presentation
The epidemiology of drug use and hepatitis C — Where are we now?
13:20
to
13:35
Main stage
Sarah Larney
13:30
Short communication
Treating drug abuse and health issues in the criminal justice system. An empirical research on the linkage of health and criminal justice interventions, France
13:30
to
13:40
Networking zone 3 (N3)
Ivana Obradovic
Short communication
Perceptions on social determinants of opioid dependence recovery
13:30
to
13:40
Networking zone 3 (N3)
Leonor Brito
Oral presentation
Substance Use Sex Index (SUSI): towards a new behaviour change assessment tool
13:30
to
13:45
Networking zone 2 (N2)
Nadine Ezard
Oral presentation
Balancing welfare and market institutional logics. Procurement regulations for social services, such as addiction treatment, in four Nordic welfare countries
13:30
to
13:45
Central square 3 (C3)
Kerstin Stenius
13:35
Oral presentation
What future strategies will enhance integration of care for drug use and hepatitis C?
13:35
to
13:50
Main stage
Jason Grebely
13:40
Short communication
Reverse transition from injecting to smoking heroin and/or crack cocaine on lower methadone dose: sub-therapeutic dosing or safer drug use?
13:40
to
13:50
Networking zone 3 (N3)
Felicia Heidebrecht
13:45
Oral presentation
Chemsex experiences: pleasures, harms and care
13:45
to
14:00
Networking zone 2 (N2)
Maitena Milhet
Oral presentation
Can liaison and diversion services increase referral to drug and alcohol treatment?
13:45
to
14:00
Central square 3 (C3)
Kate Morley
13:50
Short communication
Benzodiazepine management in primary care: barriers and facilitators
13:50
to
14:00
Networking zone 3 (N3)
Kristien Coteur
Oral presentation
How can modelling inform future interventions to integrate hepatitis C care and drug user health?
13:50
to
14:05
Main stage
Matthew Hickman
14:00
Oral presentation
The counselors’ perspective on the use of methamphetamine in a sexual context among men who have sex with men
14:00
to
14:15
Networking zone 2 (N2)
Valérie Aubut
Oral presentation
Treatment in therapeutic communities: the experience of Lisbon and Tagus Valley Region
14:00
to
14:15
Central square 3 (C3)
Elizabete Pereira
Short communication
Referral of European and third country non-national clients in Belgian drug treatment
14:00
to
14:15
Networking zone 3 (N3)
Eva Blomme
14:05
Oral presentation
What is the future role of policy makers to facilitate better integration of hepatitis C and drug user health?
14:05
to
14:20
Main stage
Ricardo Baptista Leite
14:10
Short communication
HIV and drug abuse: relationship and treatment challenges
14:10
to
14:20
Networking zone 3 (N3)
Sara Dehanov
14:15
Oral presentation
Faster, higher, stronger? Results from a Belgian survey on PED use among gym-goers
14:15
to
14:30
Networking zone 2 (N2)
Bertrand Fincoeur
Oral presentation
The influence of institutional response on the individual's recovery from drug misuse
14:15
to
14:30
Central square 3 (C3)
Carolina Cunha
14:20
Short communication
Motivation for treatment predict adherence to treatment in a randomised clinical trial
14:20
to
14:30
Networking zone 3 (N3)
Zhanna Gaulen
Oral presentation
What is required for better integration of hepatitis C and drug user health in the future: a community perspective?
14:20
to
14:35
Main stage
Mauro Guarinieri
14:30
Short communication
Psychiatric assessment of prisoners in opioid-maintenance treatment: emphasis on ADHD
14:30
to
14:40
Networking zone 3 (N3)
Marisa Silbernagl
14:35
INHSU Connecting with Care Video: Meaningful involvement of people with lived experience in HCV care delivery
14:35
to
14:40
Main stage
14:40
Short communication
Perceptions on social determinants of opioid dependence recovery
14:40
to
14:50
Networking zone 3 (N3)
15:00
Oral presentation
The EMCDDA 'Harm reduction initiative' to promote access to hepatitis testing and care
15:00
to
15:15
Central square 1 (C1)
Klaudia Palczak
Oral presentation
The contribution of injecting drug use as a risk factor for Hepatitis C virus transmission globally, regionally, and at country level: a modelling study
15:00
to
15:15
Insights zone 3 (I3)
Adam Trickey
15:15
Oral presentation
A checklist to identify barriers to HCV testing and linkage to care in drug treatment settings – an important element of a diagnostic process
15:15
to
15:25
Central square 1 (C1)
Ruth Zimmermann
Oral presentation
Factors associated with HIV and hepatitis C in the context of routes of drug administration among problem drug users in Latvia, 2018
15:15
to
15:30
Insights zone 3 (I3)
Laura Isajeva
15:25
Oral presentation
The Knowledge questionnaire for staff working with PWID: feedback from a pilot study among 150 health service workers
15:25
to
15:35
Central square 1 (C1)
Nicola Singleton
15:30
Oral presentation
Barriers in the treatment of HCV infection in drug users: inspiring solutions from SCUDO project
15:30
to
15:45
Insights zone 3 (I3)
Felice Alfonso Nava
15:35
Oral presentation
How HCV testing and care can be delivered through drug services: Evidence-base, case studies and 'real life' implementation experiences
15:35
to
15:55
Central square 1 (C1)
Dagmar Hedrich
Eberhard Schatz
15:45
Oral presentation
HCV care in an opiate substitution therapy program: assessment of infection, liver-related damage, and treatment rates.
15:45
to
16:00
Insights zone 3 (I3)
Roberto Muga
15:55
Oral presentation
Roundtable discussion: identifying barriers and facilitators to HCV testing and access to hepatitis treatment-experience from two European countries
15:55
to
16:30
Central square 1 (C1)
Nadine Berndt
Rita Cardoso Seixas
Karolina Zakrzewska
16:00
Oral presentation
Slamming, drug injection in sexual contexts: increased HIV and HCV exposure for MSM points to a need for intersectional approaches to harm reduction
16:00
to
16:15
Insights zone 3 (I3)
Marie Jauffret-Roustide
16:15
Oral presentation
Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: a systematic review and meta-analysis
16:15
to
16:30
Insights zone 3 (I3)
Jason Grebely
17:00
Oral presentation
National continua of care for HIV and hepatitis C across Europe
17:00
to
17:15
Central square 1 (C1)
Erika Duffell
17:15
Oral presentation
Continuum of care for people who inject drugs
17:15
to
17:30
Central square 1 (C1)
Thomas Seyler
17:30
Oral presentation
Continuum of care in the PWID population in Germany
17:30
to
17:45
Central square 1 (C1)
Ruth Zimmermann
17:45
Oral presentation
Continuum of care in the prison population
17:45
to
18:00
Central square 1 (C1)
Fadi Meroueh
18:00
Oral presentation
Continuum of care among the prison and PWID population in Luxembourg
18:00
to
18:15
Central square 1 (C1)
Nadine Berndt
Rita Cardoso Seixas
Thursday, 24 October
13:30
Short communication
Nurse-delivered injection education and subsequent injection drug use practices among street-involved youth
13:30
to
13:40
Networking zone 3 (N3)
Andreas Pilarinos
Oral presentation
HepCATT (Hepatitis C Assessment to Treatment Trial) in primary care: a cluster RCT of whether a complex intervention based on risk prediction algorithm tool and education can increase testing and diagnosis of HCV in primary care
13:30
to
13:45
Insights zone 1 (I1)
Matthew Hickman
13:40
Short communication
The impact of abused drugs spectrum among romanina IDU's on STI's, TB and blood born diseases in the last 10 years
13:40
to
13:50
Networking zone 3 (N3)
Adrian Abagiu
13:45
Oral presentation
Real-life effectiveness of direct-acting antiviral treatment among chronic hepatitis C infected opioid substituted patients in Germany
13:45
to
14:00
Insights zone 1 (I1)
Bernd Schulte
13:50
Short communication
Zero new infections of HIV among PWID, 4 consecutive years, a reality in Macau
13:50
to
14:00
Networking zone 3 (N3)
Augusto Nogueira
14:00
Short communication
Theory versus practice, bacteriological efficiency versus personal habits. A bacteriological and user acceptability evaluation of filtering tools for people who inject drugs.
14:00
to
14:10
Networking zone 3 (N3)
Marie Jauffret-Roustide
Oral presentation
Hepatitis C Virus (HCV) elimination and the opioid crisis: joint problems, joint solution – results of a pilot programme
14:00
to
14:15
Insights zone 1 (I1)
Brian Conway
14:10
Short communication
C+ |Be+| Be your rights... an example of community mobilisation in a neighborhood with an open scene of drug consumption in Porto.
14:10
to
14:20
Networking zone 3 (N3)
Rui Miguel Coimbra Morais
14:15
Oral presentation
Service Integration: accessing HCV treatment for homeless PWIDs/ex-PWIDs attending community OST
14:15
to
14:30
Insights zone 1 (I1)
Tina McHugh
14:20
Short communication
Innovative practices in harm reduction outreach teams in the city of Lisbon
14:20
to
14:30
Networking zone 3 (N3)
Inês Costa
Cristiana Merendeiro
14:30
Oral presentation
The cost-effectiveness of an HCV outreach intervention for at risk populations in London
14:30
to
14:45
Insights zone 1 (I1)
Zoe Ward
Oral presentation
Reduction in the population prevalence of chronic HCV among people who inject drugs associated with major scale-up of direct-acting antiviral therapy in community drug services: real world data
14:30
to
14:45
Insights zone 1 (I1)
Norah Palmateer
16:50
Oral presentation
A community-based peer-driven program to reach people who inject drugs, monitor risk behaviours and 'test and treat' for infectious diseases in Athens, Greece: ARISTOTLE HCV-HIV
16:50
to
17:05
Futures zone 1 (F1)
Vana Sypsa
17:05
Oral presentation
Uptake of testing, linkage to care, and treatment for hepatitis C infection among people who inject drugs in Australia: the ETHOS Engage Study
17:05
to
17:20
Futures zone 1 (F1)
Jason Grebely
17:20
Oral presentation
Low HCV-RNA prevalence and low anti HCV incidence in a large national sample of PWID in opioid substitution treatment in Germany: a prospective cohort study
17:20
to
17:35
Futures zone 1 (F1)
Bernd Schulte
17:35
Oral presentation
Monitoring the elimination of hepatitis C and B among people who inject drugs in Europe
17:35
to
17:50
Futures zone 1 (F1)
Thomas Seyler
17:50
Oral presentation
'Towards eliminating viral hepatitis': A critical examination of the performativity of hepatitis C elimination goals and targets
17:50
to
18:05
Futures zone 1 (F1)
Kari Lancaster
18:05
Oral presentation
Evidencing viral elimination futures: modelling, targets and the end of Hep C
18:05
to
18:20
Futures zone 1 (F1)
Tim Rhodes
18:30
Oral presentation
Re-emergence of injecting drug use-related HIV despite a comprehensive harm reduction environment
18:30
to
18:45
Insights zone 3 (I3)
Andrew McAuley
Oral presentation
New HCV prevention strategies and tools: lessons learnt
18:30
to
19:50
Networking zone 2 (N2)
Eberhard Schatz
Gabi Becker
18:45
Oral presentation
Amphetamine-type stimulant use: global and European trends in the harm reduction response
18:45
to
19:00
Insights zone 3 (I3)
Sam Shirley-Beavan
18:50
Oral presentation
HCV prevention — moderated exchange
18:50
to
19:10
Networking zone 2 (N2)
Christine Rolle
19:00
Oral presentation
Implementation of an educational intervention for safer injection in the European context: preliminary results from the EUROSIDER project
19:00
to
19:15
Insights zone 3 (I3)
Perrine Roux
19:10
Oral presentation
Short presentation of developed materials and training curricula of Integrative Drogenhilfe
19:10
to
19:20
Networking zone 2 (N2)
Christine Rolle
19:20
Oral presentation
HCV prevention — moderated discussion
19:20
to
19:30
Networking zone 2 (N2)
Gabi Becker
Friday, 25 October
10:55
Oral presentation
Overdose deaths in people prescribed opioids for chronic non-cancer pain: Systematic review and meta-analysis
10:55
to
11:10
Insights zone 3 (I3)
Sarah Larney
Oral presentation
Infectious diseases among people who inject drugs in France: the importance of acting on risk environment in an evolving crisis
10:55
to
11:10
Insights zone 4 (I4)
Marie Jauffret-Roustide
11:10
Oral presentation
Hidden aspects of the opioid crisis: what factors are driving ageing trends among those using opioid drugs?
11:10
to
11:25
Insights zone 3 (I3)
Anne Marie Carew
Oral presentation
Pakistan’s heterogeneous HIV epidemic in people who inject drugs: identifying key contributing factors
11:10
to
11:25
Insights zone 4 (I4)
Aaron Lim
11:25
Oral presentation
Comparing rates and characteristics of harms across different pharmaceutical opioids: an examination of Australian ambulance attendances 2013-2018.
11:25
to
11:40
Insights zone 3 (I3)
Tina Lam
Oral presentation
Modelling HIV transmission amongst high-risk groups to determine the extent that HIV transmission is driven by key populations and risk behaviours in Tijuana, Mexico
11:25
to
11:40
Insights zone 4 (I4)
Hannah Fraser
11:40
Oral presentation
Causes of death among patients in opioid maintenance treatment in Norway
11:40
to
11:55
Insights zone 3 (I3)
Anne Berit Bech
Oral presentation
Characteristics of polydrug use and associations with HIV risk behaviours among people who inject drugs in two cities in Europe
11:40
to
11:55
Insights zone 4 (I4)
Isabel Tavitian-Exley
11:55
Oral presentation
Increased risk of HIV and other drug-related harms associated with injecting in public places: national bio-behavioural survey of people who inject drugs
11:55
to
12:10
Insights zone 3 (I3)
Kirsten Trayner
Oral presentation
Modelling the impact of prevention and treatment interventions on HIV and Hepatitis C virus transmission among PWID in Nairobi
11:55
to
12:10
Insights zone 4 (I4)
Jack Stone
Hannah Fraser